Galapagos, Gilead announce partnership to develop JAK1-selective inhibitor
Galapagos NV and Gilead Sciences Inc. entered into an international coalition Dec. 17 to develop and commercialize the JAK1-selective inhibitor filgotinib for inflammatory disease indications. Read More »
Alerts Sign-up